Erin Reid, MD

2 days ’til 🇺🇸#ElectionDay! Have you made a plan to vote yet? 🗳️#ItsMyVote❤️🤍💙 #Election2024 ⚖️ #VoteHarrisWalz2024🦋#SaveOurDemocracy🗽#WeWontGoBack❣️

Don’t let anyone or anything stop you from making your voice heard in this election. If you have any questions or concerns, call a voter protection hotline. These folks are standing by to make sure your vote is counted. So make sure you vote! votesaveamerica.com

🩸 ASH is launching CHAMP to support career growth and development in #hematology! Join our town hall on Nov 8 at 12 noon ET to learn more about this exciting new program. RSVP today! Register now: ow.ly/alNg50TM6Wu #Mentorship #Fellows #ASHTrainee

@DrLizBrem @UCIrvineHealth @UCIAntiCancer @Bloodneoplasia Congratulations!!!🎉🎈🎊

My first IIT is officially published with lots of help and guidance from many! @UCIrvineHealth @UCIAntiCancer @Bloodneoplasia #drugrepurposing #lymsm A phase 1 study adding pitavastatin to venetoclax therapy in AML and C... sciencedirect.com/science/articl…

@NatalieRosen_MD @NatalieRosen_MD way to stay on 🎯 while building your #MedEd muscles with #ASHMEI @ASH_hematology 🩸❣️

Blood smear of the day at #ASH…

@RazzleMD @LaylaDoren1 @MedEdDocOnc Super excited about your project’s evolution and future, @RazzleMD! Has been so much fun to accompany you on the #MedEd journey in #ASHMEI with @LaylaDoren1 @ASH_hematology

Final day of presentations at ASH MEI. Grateful for all of the input from @ErinReidMD @LaylaDoren1 @MedEdDocOnc and my small group! #ASHMEI

@acweyand Much longer… for them to be concise, distilled, beautiful & engaging

Question for #MedTwitter If you’re creating slides for an entirely new hour long presentation, how long does it normally take you?

@DavidFajgenbaum Agree! Also consider other currently available on-label therapies (for rare diseases often 0) and their comparative effectiveness/ toxicity

What factors should clinicians consider when deciding to use a drug off-label? Yesterday I sat down with master repurposing clinician Dr. Luke Chen to discuss this. Here are several factors that come to mind: 1. Safety Profile: How safe is the drug? The patient’s overall health and potential risks are crucial considerations. 2. Severity of the Disease: How severe is the disease? The urgency of the situation often influences the willingness to try new treatments. 3. Mechanism of the Drug: Is there a plausible connection between the drug’s mechanism and the disease? Understanding this connection is crucial. 4. Clinical Data: Is there clinical data suggesting the drug has been effective in similar cases? Prior usage can provide valuable insights. 5. Cost of the Drug: The drug’s cost can be a significant factor. If it's exorbitantly expensive, it might change the decision-making process. 6. Patient’s Current Condition: Consideration of the patient’s current state in their disease course is essential. The decision might differ based on their immediate health status. What other factors do you think are important when considering off-label drug use? I’d love to hear your thoughts! #MedTwitter

@DavidFajgenbaum Thank you for sharing this deeply personal and beautiful story about your mom’s journey and for continuing the charge for improving health and opportunities for those with rare diseases!

My passion for finding new uses for existing drugs started long before #chasingmycure While my mom was battling brain cancer, her doctors gave her a high dose of corticosteroids which pulled her out of a coma and allowed us to have 2 additional months with her before she passed away. Those two months were some of the most special two months of my life and it was all thanks to a drug that wasn't made for her disease. Fast forward years later, I nearly died five times from a rare and deadly illness before discovering, Sirolimus, a drug that wasn’t intended for my disease, giving me 9.5 years that I never expected to have. These personal encounters highlight why I am on a mission to find new uses from existing drugs. Alongside my teams at @everycure, @pennmedicine, and @curecastleman nothing can stop us from discovering cures for patients who need them most. #MedTwitter

Funds raised through Light The Night allow LLS to fund treatments for patients who are suffering from all forms of 🩸 cancers. Since 2017, LLS has helped advance 85% of the blood cancer treatment options approved by the FDA.

I know these loved ones & patients for whom I care have had access to better therapy because of research, education & outreach provided by LLS. There is still much work to be done, which I pledge to do as a physician-researcher, & which LLS continues to critically support.

Join me in bringing light to the darkness of 🩸 cancer by donating towards @LLSusa #LightTheNight fundraise.lls.org/home I’m walking 11/4/23 with @UCSDHealth Hematology & BMT colleagues pages.lls.org/ltn/sd/SanDieg…

@DavidFajgenbaum @ElevatePrize Thank you for bringing attention to rare diseases! The fact is that many if not most rare diseases are not listed as an approved indication under any therapeutic, therefore coverage of therapy usually denied even when evidence supports the therapy.

I am incredibly honored to receive this award from The @ElevatePrize Foundation! At a time when ten million Americans are afflicted by a disease without an approved medicine and there are 3,000 drugs sitting on the pharmacy shelf that could be used in more diseases, the Elevate Prize Foundation’s support could not be more essential.

Thank you to @UCSDCardiology faculty @PamTaubMD for highlighting #POTS on @Medscape while at @escardio: Don't Fear POTS: Tips for Diagnosis and Treatment #Dysautonomia medscape.com/viewarticle/99… via @medscape

New findings published in @BloodAdvances indicate that improvements in #peripheralbloodsmear training are needed, as many institutions lack structured training programs and there are no peer-reviewed recommendations for teaching loom.ly/wv5TucM

@RepScottPeters Please sign the "Dear Colleague" letter to help address ongoing drug shortages that are reaching an all-time high, especially in hematology and oncology care. I continue to see the devastating impact these shortages are having on our patients.

Alongside 30 organizations representing patients across the U.S., ASH condemns Judge Kacsmaryk's ruling that aims to block access to #mifepristone. This decision sets a dangerous precedent that erodes the authority of @US_FDA. Read the joint statement: loom.ly/e1c0RMI

@GitaSuneja @fumikochino @LichterKatie @pre_rad @reshmajagsi Agree! While some (not all) meetings are more optimal in-person, including a virtual option improves inclusion of breadth of voices!

@AaronGoodman33 Nope - fast enough already!